Commonwealth Equity Services, LLC Sage Therapeutics, Inc. Transaction History

Commonwealth Equity Services, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$40.65 - $59.54 $208,168 - $304,904	5,121 New	5,121 $241,000
Q3 2021 Oct 29, 2021	SELL	$40.26 - $57.37 $170,662 - $243,191	-4,239 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$54.88 - $79.29 $9,384 - $13,558	-171 Reduced 3.88%	4,239 $240,000
Q1 2021 May 04, 2021	BUY	$70.65 - $96.76 $13,847 - $18,964	196 Added 4.65%	4,410 $330,000
Q4 2020 Feb 11, 2021	BUY	$58.41 - $89.06 $246,139 - $375,298	4,214 New	4,214 $364,000
Q4 2019 Feb 05, 2020	SELL	$60.18 - $154.77 $106,097 - $272,859	-1,763 Closed	0 $0
Q3 2019 Oct 30, 2019	SELL	$140.29 - $189.96 $1,262 - $1,709	-9 Reduced 0.51%	1,763 $247,000
Q2 2019 Jul 19, 2019	BUY	$157.85 - $183.09 $12,154 - $14,097	77 Added 4.54%	1,772 $324,000
Q1 2019 May 13, 2019	BUY	$89.33 - $163.65 $151,414 - $277,386	1,695 New	1,695 $269,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.